Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 80 of the 80 references it cites were found in a registry or an index.

CAR-Treg cell therapies and their future potential in treating ocular autoimmune conditions

Open access
Abraham, Alan R., Maghsoudlou, Panayiotis, Copland, David A., Nicholson, Lindsay B., Dick, Andrew D. · 2023 · Frontiers in Ophthalmology

Abstract

Ophthalmic autoimmune and autoinflammatory conditions cause significant visual morbidity and require complex medical treatment complicated by significant side effects and lack of specificity. Regulatory T cells (Tregs) have key roles in immune homeostasis and in the resolution of immune responses. Polyclonal Treg therapy has shown efficacy in treating autoimmune disease. Genetic engineering approaches to produce antigen-specific Treg therapy has the potential for enhanced treatment responses and fewer systemic side effects. Cell therapy using chimeric antigen receptor modified T cell (CAR-T) therapy, has had significant success in treating haematological malignancies. By modifying Tregs specifically, a CAR-Treg approach has been efficacious in preclinical models of autoimmune conditions leading to current phase 1-2 clinical trials. This review summarises CAR structure and design, Treg cellular biology, developments in CAR-Treg therapies, and discusses future strategies to apply CAR-Treg therapy in the treatment of ophthalmic conditions.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3389/fopht.2023.1184937

Cites

80 of 80 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Roles of Tregs in immune suppression. Tregs are activated through their antigen specific TCR. Engagement with antigen presenting cells (APCs) via the antigen specific MHC-peptide and Treg TCR interaction leads to downregulation of APC immune stimulatory activity and inflammatory cytokine production. This induces a tolerogenic phenotype in APCs suppressing Teffector cell activity. Once activated Tregs can regulate immune responses through both contact and non-contact mediated methods which themselves are not antigen specific, leading to bystander suppression of effector T-cells of different TCR specificity, and promoting infectious tolerance with the conversion of Teffector cells to Tregs. Adapted from (11).
Figure 1 Roles of Tregs in immune suppression. Tregs are activated through their antigen specific TCR. Engagement with antigen presenting cells (APCs) via the antigen specific MHC-peptide and Treg TCR interaction leads to downregulation of APC immune stimulatory activity and inflammatory cytokine production. This induces a tolerogenic phenotype in APCs suppressing Teffector cell activity. Once activated Tregs can regulate immune responses through both contact and non-contact mediated methods which themselves are not antigen specific, leading to bystander suppression of effector T-cells of different TCR specificity, and promoting infectious tolerance with the conversion of Teffector cells to Tregs. Adapted from (11).CC BY · PubMed Central
Figure 2 CAR structure and generations. CARs consist of an antigen binding domain, hinge, transmembrane domain, and single or multiple signalling domains. The 1st generation CARs sole signalling domain was the CD3ζ subunit, activating their T-cell upon CAR binding its antigen target. 2nd and 3rd generation CARs include one or two additional signalling domains respectively. These are typically CD28 and/or 4-1BB which help stabilise and enhance T-cell function. Subsequent CAR generations include more signalling domains or further subunits endowing additional functions such as cytokine or chemokine production, inducible ‘suicide’ constructs, or transcription factors. Adapted from (26).
Figure 2 CAR structure and generations. CARs consist of an antigen binding domain, hinge, transmembrane domain, and single or multiple signalling domains. The 1st generation CARs sole signalling domain was the CD3ζ subunit, activating their T-cell upon CAR binding its antigen target. 2nd and 3rd generation CARs include one or two additional signalling domains respectively. These are typically CD28 and/or 4-1BB which help stabilise and enhance T-cell function. Subsequent CAR generations include more signalling domains or further subunits endowing additional functions such as cytokine or chemokine production, inducible ‘suicide’ constructs, or transcription factors. Adapted from (26).CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 80 references

Cited by

See all 20

Metadata

Authors
Abraham, A. R., Maghsoudlou, P., Copland, D. A., Nicholson, L. B., & Dick, A. D.
Affiliations
University of Bristol (GB)
Corresponding author
  • Abraham, Alan R.
  • Dick, Andrew D.
Venue
Frontiers in Ophthalmology
Published
2023-04-18
Volume
3
Pages
1184937-1184937
ISSN
2674-0826 (ISSN-L)
OpenAlex
W4366291973
Cited by
20
References
80
Citations by year
2026: 3 · 2025: 11 · 2024: 6
FWCI
0.56
Type
journal article
Language
en
Open access
Locations
  • Frontiers in Ophthalmology (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Bristol Research (University of Bristol) (submittedVersion, cc-by)
  • Explore Bristol Research (submittedVersion, cc-by)
Funders
Moorfields Eye Charity
Topics
  • Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
  • Health Sciences › Medicine › Oncology › CAR-T cell therapy research
  • Health Sciences › Medicine › Ophthalmology › Ocular Diseases and Behçet’s Syndrome
Keywords
regulatory T cells, immune tolerance

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: CAR-Treg cell therapies and their future potential in treating ocular autoimmune conditions. https://app.cochat.ai/papers/10.3389/fopht.2023.1184937
The paper
Abraham, A. R., Maghsoudlou, P., Copland, D. A., Nicholson, L. B., & Dick, A. D. (2023). CAR-Treg cell therapies and their future potential in treating ocular autoimmune conditions. Frontiers in Ophthalmology. https://doi.org/10.3389/fopht.2023.1184937

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.